IP Library Granted Patent US 11,981,720
Granted Patent B2
US 11,981,720 · App. 18/120,007 · Granted May 14, 2024

Use novel light sensitive channel protein VR 1.0 in preparation of retinal photoreceptor cell degenerative disease drug

Inventor: Yin Shen (Hubei, CN)
Assignee: ZHONGMOU THERAPEUTICS CO., LTD.
C07K14/705A61P27/02C12N15/86A61K38/00A61K48/00C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,981,720
App. No.
18/120,007
Granted
May 14, 2024
Kind
B2
Abstract

Disclosed is a use of a novel light sensitive channel protein VR 1.0 in the preparation of a retinal photoreceptor cell degenerative disease drug, belonging to the field of biomedicine. The amino acid sequence of the present light sensitive channel protein VR 1.0 is shown in SEQ ID NO. 1, and the nucleotide sequence of the encoding gene thereof is shown in SEQ ID NO. 2. The present light sensitive channel protein VR 1.0 maintains a stable current signal under a high frequency response while having high sensitivity and fast dynamics, and also has a faster response frequency under same light stimulation conditions. The present protein has clear therapeutic effects on retinal photoreceptor cell degenerative diseases, and can be used to prepare a drug for restoring the photoreceptor function in the retina, restoring the vision or photosensitive ability of a subject, and treating retinal degenerative diseases. In the present application, a new idea for developing photogenetic therapy for retinal photosensitive cell degenerative diseases is provided, and options for clinical optogenetic therapy are expanded.

Claims (5)

1. A light-sensitive channel protein VR1.0, wherein the amino acid sequence of the light-sensitive channel protein VR1.0 comprises SEQ ID NO: 1.

2. An encoding gene of a light-sensitive channel protein VR1.0, wherein the nucleotide sequence of the encoding gene by comprises SEQ ID NO: 2.

3. A vector comprising the encoding gene of a light-sensitive channel protein VR1.0, wherein the encoding gene of the light-sensitive channel protein VR1.0 comprises SEQ ID NO: 2.

4. A medicament comprising the light-sensitive channel protein VR1.0 according to claim 1 .

5. A medicament comprising the encoding gene of a light-sensitive channel protein VR1.0, wherein the nucleotide sequence of the encoding gene comprises SEQ ID NO: 2.

Assignments (4)
CHANGE OF NAME Recorded Aug 21, 2026
From: ZHONGMOU THERAPEUTICS CO., LTD.
To: AUGELUX THERAPEUTICS LIMITED
Reel/Frame 075732/0660 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 064368 FRAME: 0343. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jul 31, 2023
From: ZHONGMOU MEDICAL TECHNOLOGY (WUHAN) CO., LTD.
To: ZHONGMOU THERAPEUTICS CO., LTD.
Reel/Frame 064436/0079 →
CHANGE OF NAME Recorded Jul 24, 2023
From: ZHONGMOU MEDICAL TECHNOLOGY (WUHAN) CO., LTD.
To: ZHONGMOU THERAPEUTICS CO., LTD.
Reel/Frame 064368/0343 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2023
From: SHEN, YIN
To: ZHONGMOU MEDICAL TECHNOLOGY (WUHAN) CO., LTD.
Reel/Frame 062946/0444 →
Priority Claims (1)
CN 202110388643.8 · Apr 12, 2021 · national
Continuity (2)
Continuation PCTCN2022097893 · Jun 9, 2022
Related Publication 20230348552A1 · Nov 2, 2023